Collegium Pharmaceutical to Release 2024 Financial Results Soon

Collegium Pharmaceutical’s Upcoming Financial Reporting

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a well-regarded biopharmaceutical company, has announced its plan to release financial results for the fourth quarter and full-year 2024. This significant milestone is scheduled for the close of the market on February 27, 2025. After the announcement, the Company intends to conduct a live conference call and a webcast for investors to discuss the results and insights into their financial performance.

Conference Call Details

The conference call is open to all interested parties, and to participate, one can simply dial (877) 407-8037 if calling from the U.S., or (201) 689-8037 for international callers. Attendees should mention the "Collegium Pharmaceutical Q4 2024 Earnings Call" to access relevant discussions. Furthermore, an audio webcast will also be available on the Company’s investor section of their official website, making it easy for stakeholders to connect and engage with the earnings announcement.

Key Information About Collegium Pharmaceutical

Collegium is on a mission to enhance the lives of individuals grappling with serious medical conditions. The Company boasts a robust portfolio centered around responsible pain management medications, which is paramount in today's healthcare landscape. Recently, Collegium improved its portfolio by acquiring Jornay PM, a groundbreaking treatment for ADHD. This acquisition marks a pivotal step in establishing a footprint in the neuropsychiatry domain, which has substantial growth potential.

Strategic Growth Initiatives

The strategic vision of Collegium includes an expansion of its commercial portfolio, with Jornay PM positioned as the flagship growth engine. The Company emphasizes a disciplined approach to capital allocation, ensuring that each investment supports their overarching goal of enhancing patient outcomes. Based in Stoughton, Massachusetts, Collegium continues to evolve and adapt, investing in innovations that resonate with their mission.

Staying Connected with Stakeholders

To maintain a clear line of communication with investors and the media, Collegium has established dedicated contacts for inquiries. Danielle Jesse, the Director of Investor Relations, leads efforts to provide shareholders with timely updates regarding the Company's financial health and strategic goals. Meanwhile, for broader media engagements, Cheryl Wheeler serves as the head of corporate communications, ensuring that all public messaging aligns with Collegium's values and objectives.

Getting in Touch

Investors looking to communicate with Collegium can reach out via email at ir@collegiumpharma.com. For media-related inquiries, they may contact Cheryl Wheeler at communications@collegiumpharma.com. These lines of communication help ensure that interested parties receive accurate and up-to-date information, reflecting the Company’s commitment to transparency.

Frequently Asked Questions

What financial results will Collegium Pharmaceutical announce?

Collegium will report its financial results for the fourth quarter and full year of 2024 during a dedicated conference call.

How can I participate in the conference call?

You can join the conference call by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international callers.

What makes Collegium Pharmaceutical unique?

Collegium focuses on responsible pain management and has recently expanded into ADHD treatments, showcasing its commitment to diverse therapeutic areas.

Where is Collegium Pharmaceutical located?

The headquarters of Collegium Pharmaceutical is located in Stoughton, Massachusetts.

How can I contact Collegium for investor relations?

For investor-related questions, you can reach out to Danielle Jesse at ir@collegiumpharma.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.